NewAmsterdam Pharma Company NV (NASDAQ: NAMS) kicked off on Tuesday, up 7.69% from the previous trading day, before settling in for the closing price of $24.71. Over the past 52 weeks, NAMS has traded in a range of $10.12-$27.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -28.76%. While this was happening, its average annual earnings per share was recorded 4.72%. With a float of $44.65 million, this company’s outstanding shares have now reached $92.17 million.
Considering the fact that the conglomerate employs 29 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 99.95%, operating margin of -495.6%, and the pretax margin is -534.64%.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of NewAmsterdam Pharma Company NV is 51.67%, while institutional ownership is 41.33%. The most recent insider transaction that took place on Dec 12 ’24, was worth 4,215,827. In this transaction 10% Owner of this company sold 166,011 shares at a rate of $25.39, taking the stock ownership to the 11,150,461 shares. Before that another transaction happened on Dec 13 ’24, when Company’s 10% Owner sold 25,751 for $25.01, making the entire transaction worth $644,048. This insider now owns 11,124,710 shares in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.72% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Take a look at NewAmsterdam Pharma Company NV’s (NAMS) current performance indicators. Last quarter, stock had a quick ratio of 10.61.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Compared to the last year’s volume of 0.37 million, its volume of 1.69 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 79.82%. Additionally, its Average True Range was 1.70.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 94.38%, which indicates a significant increase from 92.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 154.64% in the past 14 days, which was higher than the 80.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.78, while its 200-day Moving Average is $19.49. Nevertheless, the first resistance level for the watch stands at $27.53 in the near term. At $28.46, the stock is likely to face the second major resistance level. The third major resistance level sits at $30.02. If the price goes on to break the first support level at $25.04, it is likely to go to the next support level at $23.48. Should the price break the second support level, the third support level stands at $22.55.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
The company with the Market Capitalisation of 2.78 billion has total of 92,386K Shares Outstanding. Its annual sales at the moment are 14,090 K in contrast with the sum of -176,940 K annual income. Company’s last quarter sales were recorded 29,110 K and last quarter income was -16,650 K.
